Skip to main content
. 2015 Mar 9;33(5):2143–2150. doi: 10.3892/or.2015.3841

Figure 2.

Figure 2

Effect of TAT-BID on the viability of different cancer cell lines treated with doxorubicin (DOX) as determined by MTT assay. Cells were treated with 30 μg/ml TAT-BID (for PC3 and LNCaP cells) or 40 μg/ml TAT-BID (for HeLa or A549 cells) alone or in combination with either 0.5 μM (light bars) or 1 μM DOX (dark bars) for either 24 or 48 h. The average cell viability (± SD) is shown.